The clinical management of autoimmune encephalitis does not end when the acute inflammatory episode improves. This review focuses on the longitudinal phase of care, addressing long-term immunosuppression, monitoring, biomarkers, outcome measurement and persistent neurological symptoms. The authors note that early diagnosis and treatment are associated with better neurological outcomes, particularly in disorders targeting neuronal surface or synaptic proteins. However, patients may continue to experience cognitive, psychiatric, movement or seizure-related problems after the initial inflammatory phase has settled. The paper therefore supports a structured follow-up strategy rather than viewing recovery as complete when the acute illness resolves. For HCPs, persistent cognitive or behavioural symptoms should prompt reassessment rather than being assumed to represent irreversible damage. Decisions about prolonged immunotherapy require balancing relapse risk against infection and treatment toxicity, and the evidence for newer agents remains less mature than for traditional therapy. Rehabilitation, neuropsychological assessment and symptom-directed care are also important. This longitudinal approach fits IANCON's emphasis on neuroimmunology, neuropsychology and clinical case-based management, while highlighting the need for multidisciplinary follow-up in patients with potentially reversible encephalopathy.